Latest Derivatives News

ImpediMed has secured FDA 510(k) clearance for its SOZO Digital Health Platform to assess sarcopenia risk, marking it as the only FDA-cleared bioimpedance spectroscopy solution for this clinical application. This clearance enables clinicians to non-invasively monitor muscle loss in cancer and chronic disease patients, potentially improving treatment outcomes.

Nimy Resources has confirmed extensive soil geochemistry anomalies for gold and base metals at its Mons Project in Western Australia, setting the stage for a detailed ground electromagnetic survey and maiden drilling.

Patagonia Lithium’s Well 7 delivers strong porosity alignment between core and gamma surveys, with lithium levels near project averages. Preparations for Well 8 pump testing advance, while plans for Well 9 await regulatory approval.

Southern Cross Electrical Engineering’s FY26 underlying profits surged despite a $46.1 million WestConnex arbitration settlement dragging statutory net profit sharply lower. The group declared a record dividend and raised FY27 EBITDA guidance by 30%.

Westgold Resources has declared a maiden Ore Reserve of 1.1 million ounces at its Fletcher deposit, marking a significant 30% increase in total Mineral Resources at Beta Hunt and advancing plans for a 4Mtpa processing expansion.

SRG Global reported record FY26 results driven by strong operational delivery, strategic acquisition of TAMS, and enhanced sustainability governance. The company upgraded its FY27 EBITDA guidance to $195–205 million, supported by a $5.1 billion work in hand and $11.5 billion opportunity pipeline.

Regal Asian Investments (ASX:RG8) posted a stellar FY26 with a net profit after tax of $124.8 million, driven by a 52.6% net portfolio return and a 10 cent fully franked final dividend, reflecting strong exposure to Asian semiconductors amid the AI boom.

The Calmer Co. has locked in an exclusive global distribution agreement for its kava extract ingredients, underpinning a potential A$25 million revenue stream over three years across key markets including the US and ASEAN.

Global X Metal Securities Australia Limited has refreshed its prospectus for five classes of precious metals securities, maintaining physical bullion backing and ASX AQUA listing, with detailed disclosures on structure, fees, risks, and tax implications.

Accelerate Resources has identified over 200 manganese outcrops spanning nearly 10 hectares at its Woodie Woodie North Project, with rock-chip assays hitting up to 58.4% manganese. The company is gearing up for its maiden reverse circulation drilling campaign in September 2026.

ASX Limited reported a 13.3% rise in operating revenue to $1.25 billion for FY26, with underlying net profit up 5.2%, despite a 3.5% dip in statutory profit due to significant one-off costs including a $20.5 million ASIC penalty. The company declared a fully franked final dividend of 104.7 cents per share and appointed Anthony Attia as CEO.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.